MENU
+Compare
QNCX
Stock ticker: NASDAQ
AS OF
May 9 closing price
Price
$1.02
Change
-$0.01 (-0.97%)
Capitalization
45.01M

QNCX Quince Therapeutics Forecast, Technical & Fundamental Analysis

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases... Show more

Industry: #Biotechnology
QNCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for QNCX with price predictions
May 09, 2025

Momentum Indicator for QNCX turns negative, indicating new downward trend

QNCX saw its Momentum Indicator move below the 0 level on May 07, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In of the 82 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for QNCX moved below the 200-day moving average on May 06, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QNCX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

QNCX broke above its upper Bollinger Band on April 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for QNCX entered a downward trend on April 23, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QNCX's RSI Oscillator exited the oversold zone, of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for QNCX just turned positive on April 23, 2025. Looking at past instances where QNCX's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where QNCX advanced for three days, in of 230 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.493) is normal, around the industry mean (14.703). P/E Ratio (0.000) is within average values for comparable stocks, (64.016). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.990). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.016).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. QNCX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QNCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
QNCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

QNCX is expected to report earnings to fall 32.14% to -18 cents per share on May 13

Quince Therapeutics QNCX Stock Earnings Reports
Q1'25
Est.
$-0.19
Q4'24
Missed
by $0.10
Q3'24
Missed
by $0.03
Q1'23
Missed
by $0.03
Q4'22
Beat
by $0.14
The last earnings report on March 24 showed earnings per share of -28 cents, missing the estimate of -17 cents. With 156.98K shares outstanding, the current market capitalization sits at 45.01M.
A.I. Advisor
published General Information

General Information

a developer of novel disease-modifying therapeutic for alzheimer's and other degenerative diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
611 Gateway Boulevard
Phone
+1 415 910-5717
Employees
32
Web
https://www.quincetx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GPRO0.620.01
+1.18%
GoPro
BNS50.250.16
+0.32%
Bank of Nova Scotia
ZWS35.200.03
+0.09%
Zurn Elkay Water Solutions Corp
NABL7.52-0.03
-0.40%
N-able
ICAD3.60-0.08
-2.17%
iCAD

QNCX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, QNCX has been loosely correlated with MNPR. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if QNCX jumps, then MNPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QNCX
1D Price
Change %
QNCX100%
-0.97%
MNPR - QNCX
35%
Loosely correlated
-6.96%
CCCC - QNCX
33%
Poorly correlated
-4.55%
ADCT - QNCX
31%
Poorly correlated
-0.78%
CLNN - QNCX
29%
Poorly correlated
+1.94%
KOD - QNCX
28%
Poorly correlated
-5.75%
More